GLP-1 medications, such as semaglutide and tirzepatide, are gaining attention for their ability to support weight loss and improve metabolic health.
Vigor Compounding supports healthcare providers offering compounded GLP-1 therapy options by working with trusted, licensed 503A compounding pharmacy partners. These programs may include compounded semaglutide and tirzepatide formulations, including options with vitamin B6 when clinically appropriate.
When providers incorporate compounded GLP-1 medications into patient care, informed consent is an essential step in promoting transparency, setting expectations, and supporting safe treatment decisions.
This blog walks through key elements that providers may consider including in informed consent documentation for GLP-1 therapies.
Why Informed Consent Matters
Clear, well-structured informed consent documents help protect your practice and support patient understanding. A thorough consent process can also reinforce transparency, which is especially important when working with compounded medications.
Typically, providers obtain patient signatures on these documents and review key topics during a clinical discussion before treatment begins.
Elements to Include in Your GLP-1 Informed Consent Form
Below are several sections commonly included in GLP-1 informed consent forms.
Therapy Overview
Consent documents should explain what GLP-1 receptor agonists are and how they may support weight management. It is also helpful to clarify the difference between compounded medications and FDA-approved branded products.
Treatment Expectations
Patients should understand:
-
Expected outcomes may vary
-
Treatment requires ongoing clinical monitoring
-
Lifestyle factors such as nutrition and activity remain important
Potential Risks and Side Effects
Patients should be informed about possible side effects, including:
-
Common gastrointestinal effects
-
Potential serious risks
-
Interactions with other medications
Off-Label and Compounded Use Disclosure
A key consent component is disclosure that compounded prescriptions may differ from commercially manufactured drugs and may be prescribed in cases where individualized dosing or formulation is needed.
Patients should also be informed if a medication is being used off-label.
Patient Responsibilities
Your consent form may outline patient responsibilities, such as:
-
Following prescribed dosing schedules
-
Reporting adverse effects promptly
-
Attending follow-up appointments and ongoing monitoring
Alternatives to Treatment
Patients should be made aware that they have the right to decline or discontinue treatment and should understand what alternative options may exist.
Set Your Practice Up for Success
Informed consent is more than paperwork. It is a foundational step in patient care and helps support safe, compliant therapy delivery.
A clear and complete consent process reduces liability and builds trust. The quality of patient education matters just as much as the medication process itself.
If you are looking for support resources or guidance on connecting with trusted, licensed 503A compounding pharmacy partners for GLP-1 therapy programs, Vigor Compounding is here to help.
Reach out today to learn how we can assist with your prescribing needs.
